Current Hepatitis Reports

, Volume 5, Issue 1, pp 14–22

Newer antiviral agents and therapeutic approaches for chronic hepatitis b

Authors

    • Department of GastroenterologyUniversity of California, San Francisco
Article

DOI: 10.1007/s11901-006-0018-8

Cite this article as:
Yao, F.Y. Curr hepatitis rep (2006) 5: 14. doi:10.1007/s11901-006-0018-8
  • 23 Views

Abstract

A new era in the treatment of chronic hepatitis B began approximately a decade ago. Three oral nucleoside or nucleotide analogues—lamivudine, adefovir dipivoxil, and entecavir—are now approved in the United States for the treatment of chronic hepatitis B. Other new oral agents, including telbivudine, clevudine, and emtricitabine, are in various stages of clinical investigation. This article reviews the efficacy and resistance data of these oral antiviral agents, and the preliminary results of combination therapy for chronic hepatitis B.

Copyright information

© Current Science Inc 2006